A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Sponsor: |
BioMed Valley Discoveries, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT6805 |
U.S. Govt. ID: |
NCT04488003 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not received authorization to be marketed for use within the USA. Ulixertinib works by inhibiting (blocking) tumor cells ' EKR1/2 pathways, which can cause the tumor to stop growing or spreading. Cancers include bladder cancer, colon and rectal cancer, head and neck, kidney cancer, liver cancer, lung cancer, pancreatic cancer, and prostate cancer.
This study is closed
Investigator
Richard Carvajal, MD
Are you at least 18 years old? |
Yes |
No |
Do you have advanced cancer that has genetic mutations? |
Yes |
No |
Has your cancer gotten worse while taking prior therapy? |
Yes |
No |